Our site uses cookies to offer better navigation usability. The cookies we use do not in any way allow us to identify you directly. If you want to know more, or deny consent to all or some cookies, click here to disable them. If you continue browsing the site you consent to the use of cookies. ADDITIONAL INFORMATION WORK WITH US ETHICS AND COMPLIANCE CONTACT US Healthcare is our mission HOME COMPANY R&D THERAPEUTIC AREAS PRODUCTS ROLLING ALONG THE DAY Parkinson's disease is the second most common neurodegenerative disease in the world and is typical of old age. In Italy it is estimated that about 230,000 people are affected, of which 5% aged <50 years (genetic forms), while 70%> 65 years (sporadic forms). DISCOVER + OUR PRODUCTS Lusofarmaco can boast a wide know-how in various therapeutic areas: from cardiovascular pathologies to respiratory diseases, from antibiotic therapy to neuropsychiatry and finally the gynecological area. DISCOVER + RESEARCH AND DEVELOPMENT For many years, the connotation of Lusofarmaco has been that of a company of essentially national importance, with a list focused on drugs with consolidated experience. DISCOVER + PHARMACOVIGILANCE It is the science of identifying, evaluating, understanding and preventing adverse effects or any other drug-related problem. DISCOVER + SINCE 1983 LUSOFARMACO HAS BEEN PART OF THE MENARINI GROUP A fundamental step in the history of Lusofarmaco was, in 1983, the entry into the Menarini Group, which gave the company a more international connotation and the possibility of expanding its list with innovative drugs, thanks to important investments in the Research sector and Development. DISCOVER THE # QUALITÀMENARINI + PHARMACOVIGILANCE WORK WITH US TERMS AND CONDITIONS PRIVACY POLICY AT THE SERVICE OF THE DOCTOR AND PHARMACIST Registered office: Milanofiori - Strada 6, Edificio L - 20089 Rozzano (MI) Tel. 02-516555.1 - Fax 02-516555.249 Company register number: 00714810157 Company register office: Milan Capital: € 130,000 IV Capital resulting from the latest financial statements: € 130,000 Company subject to the management and coordination of A. Menarini Industrie Farmaceutiche Riunite Srl SITE MAP Copyright 2017 Istituto Lusofarmaco D'Italia SpA